These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 10636147

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.
    Durelli L, Barbero P, Bergui M, Versino E, Bassano MA, Verdun E, Ferrero B, Rivoiro C, Ferrero C, Picco E, Ripellino P, Viglietti D, Giuliani G, Montanari E, Clerico M, OPTIMS Study Group.
    J Neurol; 2008 Sep; 255(9):1315-23. PubMed ID: 18825438
    [Abstract] [Full Text] [Related]

  • 25. History of modern multiple sclerosis therapy.
    Lublin F.
    J Neurol; 2005 Sep; 252 Suppl 3():iii3-iii9. PubMed ID: 16170498
    [Abstract] [Full Text] [Related]

  • 26. Immunomodulatory effects of interferon-beta-1b in patients with multiple sclerosis.
    Ossege LM, Sindern E, Patzold T, Malin JP.
    Int Immunopharmacol; 2001 Jun; 1(6):1085-100. PubMed ID: 11407304
    [Abstract] [Full Text] [Related]

  • 27. The IFN-β 1b effect on Cu Zn superoxide dismutase (SOD1) in peripheral mononuclear blood cells of relapsing-remitting multiple sclerosis patients and in neuroblastoma SK-N-BE cells.
    Damiano S, Sasso A, De Felice B, Terrazzano G, Bresciamorra V, Carotenuto A, Orefice NS, Orefice G, Vacca G, Belfiore A, Santillo M, Mondola P.
    Brain Res Bull; 2015 Sep; 118():1-6. PubMed ID: 26327496
    [Abstract] [Full Text] [Related]

  • 28. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.
    Bertolotto A, Gilli F, Sala A, Capobianco M, Malucchi S, Milano E, Melis F, Marnetto F, Lindberg RL, Bottero R, Di Sapio A, Giordana MT.
    Neurology; 2003 Feb 25; 60(4):634-9. PubMed ID: 12601105
    [Abstract] [Full Text] [Related]

  • 29. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients.
    Gneiss C, Tripp P, Reichartseder F, Egg R, Ehling R, Lutterotti A, Khalil M, Kuenz B, Mayringer I, Reindl M, Berger T, Deisenhammer F.
    Mult Scler; 2006 Dec 25; 12(6):731-7. PubMed ID: 17263000
    [Abstract] [Full Text] [Related]

  • 30. Evaluation of serum levels of chemokines during interferon-β treatment in multiple sclerosis patients: a 1-year, observational cohort study.
    Comini-Frota ER, Teixeira AL, Angelo JP, Andrade MV, Brum DG, Kaimen-Maciel DR, Foss NT, Donadi EA.
    CNS Drugs; 2011 Nov 01; 25(11):971-81. PubMed ID: 22054120
    [Abstract] [Full Text] [Related]

  • 31. Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis.
    Khademi M, Wallström E, Andersson M, Piehl F, Di Marco R, Olsson T.
    J Neuroimmunol; 2000 Mar 01; 103(2):202-10. PubMed ID: 10696916
    [Abstract] [Full Text] [Related]

  • 32. [Interferons beta in patients with multiple sclerosis].
    Vlasov IaV, Kuznetsova NI, Poverennova IE, Khivintseva EV.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005 Mar 01; 105(7):54-5. PubMed ID: 16117149
    [No Abstract] [Full Text] [Related]

  • 33. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A.
    Cochrane Database Syst Rev; 2016 Nov 24; 11(11):CD009333. PubMed ID: 27880972
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Neutralizing antibodies to multiple sclerosis treatments.
    Rossman HS.
    J Manag Care Pharm; 2004 Jun 24; 10(3 Suppl B):S12-9. PubMed ID: 15253685
    [Abstract] [Full Text] [Related]

  • 36. A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging.
    Jeffery DR, Chepuri N, Durden D, Burdette J.
    Mult Scler; 2005 Jun 24; 11(3):296-301. PubMed ID: 15957510
    [Abstract] [Full Text] [Related]

  • 37. Blood levels of transforming growth factor-beta 1 (TGF-beta1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-beta1b).
    Nicoletti F, Di Marco R, Patti F, Reggio E, Nicoletti A, Zaccone P, Stivala F, Meroni PL, Reggio A.
    Clin Exp Immunol; 1998 Jul 24; 113(1):96-9. PubMed ID: 9697990
    [Abstract] [Full Text] [Related]

  • 38. Contrasting responses to interferon beta-1b treatment in relapsing-remitting multiple sclerosis: does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment?
    van Boxel-Dezaire AH, van Trigt-Hoff SC, Killestein J, Schrijver HM, van Houwelingen JC, Polman CH, Nagelkerken L.
    Ann Neurol; 2000 Sep 24; 48(3):313-22. PubMed ID: 10976637
    [Abstract] [Full Text] [Related]

  • 39. The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up.
    Reggio E, Nicoletti A, Fiorilla T, Politi G, Reggio A, Patti F.
    J Neurol; 2005 Oct 24; 252(10):1255-61. PubMed ID: 15940386
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.